Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Xynomic Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05275374CT.gov XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thyroid Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| XP-102 (this asset) | Xynomic Pharmaceuticals, Inc. | P1/2 | CC · 45 |
| Pembrolizumab | Kineta Inc. | P2 | BB |
| Alectinib | Hoffmann-La Roche | P2 | B |
| Denosumab | Amgen | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| [18F]F-RESCA-T4 | RenJi Hospital | P2/3 | CCC |
| [18f]f-resca-rt4 | RenJi Hospital | P2/3 | CCC |
| [68ga]ga-nota-rt4 | RenJi Hospital | P2/3 | CCC |
| [68ga]ga-nota-t4 | RenJi Hospital | P2/3 | CCC |
+42 more in the Thyroid Cancer cohort
Other indications for XP-102
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 47 |
| Cancer | — | P1/2 | CC · 41 |
| Melanoma | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. XP-102 in Thyroid Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/xp-102-thyroid-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →